Application of a liquid chromatography–tandem mass spectrometry (LC–MS/MS) method to the pharmacokinetics, tissue distribution and excretion studies of felotaxel (SHR110008) in tumor-bearing mice

Felotaxel (SHR110008), currently under clinical investigation in phase I trial, is a new effective taxane with greater anticancer activity and less toxicity than docetaxel. Pharmacokinetic studies in animal models are the important components in clinical development of this agent. In this study, a rapid and sensitive analytical method based on high-performance liquid chromatography–tandem mass spectrometry (LC–MS/MS) has been developed for the determination of felotaxel in tumor-bearing mice plasma, urine, feces and tissues (brain, heart, liver, lung and kidney and tumor). For all matrices, sample preparation involved liquid–liquid extraction with ethyl acetate. Calibration curves (1/x2 weighted) offered satisfactory linearity (r2 ≥ 0.995) within the test range. The lower limit of quantitation (LLOQ) for all matrices was 10 ng/ml except that for mouse plasma and brain LLOQ was 1 ng/ml. The accuracy and precision ranged from 86.1 to 107.2% and 1.1 to 9.2%, respectively. Recoveries (73.9–96.1%) and matrix effects (76.4–97.2%) were satisfactory in all the biological matrices examined. Stability studies (85.1–101.5%) showed that felotaxel was stable both during the assay procedure and long-term storage. The assay was successfully applied to plasma pharmacokinetics, tissue distribution and excretion study of mice. The pharmacokinetic parameters, such as half-life, mean residence time, maximum concentration were determined. The preclinical data are useful for the design of clinical trials of felotaxel.

► Felotaxel, under clinical investigation, is a new effective taxane.
► This is a novel method for the quantitation of felotaxel in mice biological samples.
► It is the first report about pharmacokinetics profiles of felotaxel mice.